Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Biosceptre ( Aust ) Pty Ltd. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and 1 distinct art unit, indicating a concentrated prosecution focus. The alignment of the action with the assigned unit suggests a specific technical niche for the current intellectual property efforts.
The busiest examiner for this portfolio is JOHANSEN, PETER N., who is responsible for 1 busiest_examiner_pending. This individual workload matches the total volume of 1 pending office action for the entire portfolio, reflecting a direct relationship between the examiner and the pending matters. Practitioners should note that with only 1 distinct examiner involved, the progress of the matters depends on the specific review pace of this individual.
Because there is only 1 distinct art unit involved, the prosecution strategy does not currently require navigating different procedural norms across multiple units. The presence of the action under JOHANSEN, PETER N. means that upcoming responses will be directed to this specific individual. This concentration simplifies the communication channel for the current workload in the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SZPERKA, MICHAEL EDWARD | 1 | 62.9% | +36.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18285621 | METHODS FOR CONTROLLING IMMUNE CELL ACTIVITY | SZPERKA, MICHAEL EDWARD | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18285621 | METHODS FOR CONTROLLING IMMUNE CELL ACTIVITY | SZPERKA, MICHAEL EDWARD | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18285621 | METHODS FOR CONTROLLING IMMUNE CELL ACTIVITY | SZPERKA, MICHAEL EDWARD | 1641 | §102§112 | Non-Final OA | — | Pending | Oct 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial